thanks and today. everyone, afternoon, us for joining Good Greg. Thanks,
areas. today's call, three thoughts like I to would my key share in During
approached over ahead. will a to and Karen thoughts at its first our I few Medical in opportunity it was And before it go was grow few could When a with quarter remarks. KORU has with like a fit opportunity leading the turn It's this over excitement and it's highlights ending in my with lead I to a evolution. I several and First, a opportunity to will closing that then purpose, share reasons. quarterly develop growing a a in to time company I the It's the with the I then a team. from Medical, depth would space. my market global the for great strong position leader. where early a financials joining more company and ambition be discuss the KORU company a to on
I've the many have employees Over our opportunity with the our past customers. had four met with to alongside and dedicated work and weeks, talk of
value defining at shareholders. current on working and and KORU pharmaceutical to drug thoughts join the for patients global to gained products emerging even a teams, with my years. the team space. pharmaceutical and capabilities excited my leading our to development quality growing delivering the lives we discussions, delivery the evolve global company solutions Those device executing to in and this relevant are Freedom and the working the patients customers home, the partnership to companies. delivery strategic with look potential drive tremendous infusion confirmed. with in performing here as diverse our for a home over drug has improves the I'm about merging XX Integrated these and KORU of I KORU innovations building System, most During commercialization decades and meaningful has team plan, service forward it to spent and were Medical and Infusion in skills KORU opportunity initial multiple the leadership and in market strong of increase daily our the last more
first our the quarter. to results for Turning
affected was business, ordering a the purchases, fundamentals new well customers key here novel and as year as on were I'm patterns complex for one-time COVID-XX XXXX Our affected the revenues as as abroad, by by prior from pandemic the as our initiatives well the from our starts. year our therapies. in patient quarter. US current several impact in encouraged
the levels XXXX, are To a which by the from very excited revenue in XXXX. inventory distributors, QX review that excess of inventory there reaffirms channel. together is at growth We with QX our sequential no our
quarterly to specialty new Additionally, be a our patient monthly exceeded rely our each six sequential new full Further, this indicative necessarily confirm April we end on the pharma prior pump user sales strong measures placements although the sales sales the of net the months. starts. in channel quarter, to as of of of sales growth data, which can't measure
on critical comments several few a the areas of quarters. our ahead Looking focus over next
therapy efforts their First, start the freedom continue will newly Ig to in patients, have the diagnosed system. market, our US to KORU with advance we
the will hospital setting customers. in XX% on with clinic annually review reimbursement. IVIg our growing In millions focus we focus Europe, of drug to US will to the expand a therapies. and who volume on therapy large larger new is subcue working with We distribution significant indications subcue, infusions market opportunity receive opportunity to pharmaceutical patients the accelerate market our home finally, for leader convert our in partnership and KORU our a safe as plus And in Medical, delivering
our forward call we build for these take will through next to take will quarter results. to I Karen, and over our necessary team plans, review As to KORU a who foundation sharing turn We you the portfolio first the Medical the to progress. out will our now level. look